Safeguarding Women from Chemical Abortion Act
- Bill Number
- S. 4066
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-03-11: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-06-24T11:03:29Z
AI-Generated Summary
Purpose
The legislation, titled the "Safeguarding Women from Chemical Abortion Act," aims to revoke federal approval for the drug mifepristone (also known as RU-486 or Mifeprex) when used to end an intrauterine pregnancy (a pregnancy developing inside the uterus). It also seeks to create new legal accountability for harms caused by this and similar chemical abortion drugs, while clarifying that it does not alter existing federal laws on mailing certain materials.
Key Provisions
- Withdrawal of Drug Approval (Section 2):
- After 14 days from enactment, the Food and Drug Administration (FDA) approval for mifepristone—under the Federal Food, Drug, and Cosmetic Act—for ending pregnancies is treated as withdrawn.
- This applies to both the original approval and any generic versions referencing it.
- Distributing or selling mifepristone for this purpose becomes a violation, punishable under existing FDA rules (e.g., fines or seizures).
- Any labeling suggesting mifepristone can be used for pregnancy termination (alone or with another drug) makes the product "misbranded," subject to FDA enforcement.
- Federal Tort for Harms from Chemical Abortion Drugs (Section 3):
- Defines "covered entities" as manufacturers who produce mifepristone for pregnancy termination and introduce it into interstate commerce (trade across state lines).
- Holds these manufacturers liable for any bodily injury or mental health harm (physical, psychological, emotional, or physiological) linked to the drug's use.
- Allows affected individuals to sue in federal or state courts for compensatory damages (to cover losses), punitive damages (to punish wrongdoing), and attorney fees/costs.
- Does not override state laws providing additional remedies.
- Takes effect 90 days after enactment.
- Rule of Construction (Section 4):
- Explicitly states the act does not change federal law under 18 U.S.C. § 1461, which prohibits mailing obscene materials, contraceptives, or items promoting crimes (including some abortion-related restrictions).
Significant Changes to Existing Law
- Drug Approval Revocation: Overrides the FDA's prior approval of mifepristone for medical abortion (granted in 2000 and expanded in 2016 and 2021), effectively banning its legal use for this purpose nationwide without new approval processes.
- New Liability Framework: Introduces a specific federal civil claim (tort) for harms from mifepristone, expanding beyond general product liability laws by targeting "chemical abortion drugs" and allowing direct lawsuits against manufacturers.
- Enforcement Enhancements: Treats post-withdrawal distribution as a violation of FDA rules, potentially increasing penalties for misbranding and interstate commerce of the drug.
Potential Impacts
- On Government Agencies: The FDA would enforce the withdrawal, leading to increased inspections, seizures, and legal actions against violators. Courts may see a rise in lawsuits, straining federal and state judicial resources.
- On Citizens: Women who have used or might use mifepristone could face limited access to this medication for abortion (about 5% of U.S. pregnancies end this way), potentially increasing reliance on surgical options or travel for care. Those harmed could pursue compensation, but proving causation (link between drug and injury) might be challenging.
- On International Relations: Minimal direct impact, though it could affect U.S. pharmaceutical exports or collaborations if mifepristone is involved; foreign manufacturers might face U.S. import restrictions.
Main Stakeholders Affected
- Manufacturers and Pharmaceutical Companies: Entities like Danco Laboratories (current U.S. marketer of Mifeprex) face approval loss, distribution bans, and heightened lawsuit risks, potentially leading to financial losses or market exit.
- Women and Patients: Primary users of mifepristone for abortion; they gain a new avenue for suing over harms but lose federally approved access to the drug.
- Healthcare Providers: Doctors, clinics, and pharmacies prescribing or dispensing mifepristone could violate laws if they continue, risking professional penalties or supply shortages.
- FDA and Regulators: Must implement and enforce the changes, shifting from oversight to prohibition.
- Advocacy Groups: Pro-life organizations may support it for restricting abortion access; reproductive rights groups could oppose it for limiting options.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: The approval withdrawal could prompt challenges under administrative law, as it bypasses standard FDA procedures for drug removal (e.g., safety reviews). The tort provision creates a novel federal remedy, potentially overlapping with state product liability suits without conflicting.
- Constitutional Implications: May invite lawsuits claiming violations of due process (unfair revocation of approved medical treatments) or equal protection (disparate impact on women's reproductive rights). Post-Dobbs v. Jackson Women's Health Organization (2022 Supreme Court decision overturning federal abortion protections), this aligns with state-level restrictions but tests federal limits on medication access.
- Political Implications: As a Senate-introduced bill (by Sen. Hawley, referred to the Health Committee in March 2026), it reflects ongoing national debates on abortion post-Roe v. Wade reversal, potentially polarizing Congress and influencing 2026 midterm elections or future FDA policies.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (7)
Sen. Cornyn, John [R-TX], Sen. Blackburn, Marsha [R-TN], Sen. Budd, Ted [R-NC], Sen. Tuberville, Tommy [R-AL], Sen. Moreno, Bernie [R-OH], Sen. Lankford, James [R-OK], Sen. Rounds, Mike [R-SD]
Recent Actions
- 2026-03-11: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2026-03-11: Introduced in Senate
Bill Versions
- Safeguarding Women from Chemical Abortion Act — issued 2026-03-11 — PDF (4 pages)